Exchangeable Senior Subordinated Notes News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Exchangeable senior subordinated notes. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Exchangeable Senior Subordinated Notes Today - Breaking & Trending Today

Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Resubmission of NDA On Track for Early Q2 24— Cash Runway into 2025, including through Potential FDA Approval in Early Q4 24 Company to host conference call today at 8:30amET DUBLIN, Ireland and CHICAGO, March 28, 2024 (GLOBE NEWSWIRE) Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today r ....

United States , Judy Matthews , Corey Fishman , Drug Administration , Recourse Royalty , Cash Runway , Chief Executive , Special Protocol Assessment , Resistant Enterobacterales , Complete Response Letter , Financial Advisor , Full Year , Prescription Drug User Fee Act , Exchangeable Senior Subordinated Notes , Iterum Therapeutics , Qualified Infectious Disease Product , Fast Track , Exchangeable Notes , Royalty Linked Notes , Maturity Date , Private Securities Litigation Reform Act , Nasdaq Capital Market , Annual Report , Financial Officer , Consolidated Statement ,

2024-03-28 | NDAQ:ITRM | Press Release | Iterum Therapeutics plc

(2024-03-28 | NDAQ:ITRM) Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results ....

United States , Iterum Closecurlyquote , Corey Fishman , Judy Matthews , Drug Administration , Recourse Royalty , Cash Runway , Chief Executive , Special Protocol Assessment , Resistant Enterobacterales , Complete Response Letter , Financial Advisor , Full Year , Prescription Drug User Fee Act , Linked Notes Closecurlydoublequote , Exchangeable Senior Subordinated Notes , Notes Closecurlydoublequote , Iterum Therapeutics , Qualified Infectious Disease Product , Fast Track , Exchangeable Notes , Maturity Date Closecurlydoublequote , Royalty Linked Notes , Maturity Date , Private Securities Litigation Reform Act , Nasdaq Capital Market ,

Iterum Therapeutics Reports Second Quarter 2023 Financial Results

Iterum Therapeutics Reports Second Quarter 2023 Financial Results
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , Judy Matthews , Corey Fishman , Drug Administration , Japanese Patent Office , Recourse Royalty , Complete Enrollment , Topline Data Expected , Cash Runway , Chief Executive , Trial Ongoing , Resistant Enterobacterales , Japanese Patent Issued , Japanese Patent Registration , Beta Lactam Compounds , Iterum Therapeutics , Qualified Infectious Disease Product , Fast Track , Exchangeable Senior Subordinated Notes , Exchangeable Notes , Maturity Date , Royalty Linked Notes , Private Securities Litigation Reform Act , Nasdaq Capital Market , Quarterly Report , Financial Officer ,

Iterum Therapeutics Announces Date of 1-for-15 Reverse Share Split

Iterum Therapeutics Announces Date of 1-for-15 Reverse Share Split
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , Exchange Commission , Company Board Of Directors , Board Of Directors The Company , Nasdaq Capital Market , Annual General Meeting , Nasdaq Listing Rule , Bid Price , Exchangeable Senior Subordinated Notes , Iterum Therapeutics , Qualified Infectious Disease Product , Fast Track , Annual Report , Judy Matthewschief Financial Officer ,

Iterum Therapeutics Announces Date of 1-for-15 Reverse

DUBLIN, Ireland and CHICAGO, Aug. 16, 2022 (GLOBE NEWSWIRE) Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical. ....

United States , Judy Matthews , Exchange Commission , Company Board Of Directors , Board Of Directors The Company , Nasdaq Capital Market , Annual General Meeting , Nasdaq Listing Rule , Bid Price , Exchangeable Senior Subordinated Notes , Iterum Therapeutics , Qualified Infectious Disease Product , Fast Track , Annual Report , Nasdaq Itrm , Iterum Therapeutics Plc ,